Phathom Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHAT research report →
Companywww.phathompharma.com
Phathom Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
- CEO
- Steven L. Basta
- IPO
- 2019
- Employees
- 427
- HQ
- Florham Park, NJ, US
Price Chart
Valuation
- Market Cap
- $946.70M
- P/E
- -6.19
- P/S
- 4.62
- P/B
- -2.89
- EV/EBITDA
- -8.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.93%
- Op Margin
- -47.15%
- Net Margin
- -76.77%
- ROE
- 39.24%
- ROIC
- -53.45%
Growth & Income
- Revenue
- $175.11M · 216.93%
- Net Income
- $-221,247,000 · 33.82%
- EPS
- $-3.03 · 42.72%
- Op Income
- $-159,986,000
- FCF YoY
- 37.52%
Performance & Tape
- 52W High
- $18.31
- 52W Low
- $3.69
- 50D MA
- $11.71
- 200D MA
- $12.79
- Beta
- 0.57
- Avg Volume
- 1.24M
Get TickerSpark's AI analysis on PHAT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 26 | Parikh Asit | other | 40,000 |
| Mar 10, 26 | Parikh Asit | other | 40,000 |
| Feb 27, 26 | Breedlove Robert Charles | other | 2,790 |
| Feb 27, 26 | Breedlove Robert Charles | other | 964 |
| Feb 27, 26 | Breedlove Robert Charles | other | 414 |
| Feb 27, 26 | Breedlove Robert Charles | other | 13,000 |
| Feb 10, 26 | Cook Anne Marie | other | 3,461 |
| Feb 10, 26 | Cook Anne Marie | other | 1,535 |
| Feb 10, 26 | Basta Steven L | other | 12,362 |
| Feb 10, 26 | Basta Steven L | other | 6,277 |
Our PHAT Coverage
We haven't published any research on PHAT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHAT Report →